<DOC>
	<DOCNO>NCT03093922</DOCNO>
	<brief_summary>The purpose study compare good bad effect study drug atezolizumab cancer combine standard chemotherapy drug gemcitabine cisplatin ( GC ) two different dose schedule : chemotherapy ( GC ) atezolizumab vs. GC atezolizumab .</brief_summary>
	<brief_title>A Study Two Dosing Schedules Atezolizumab Combination With Gemcitabine Cisplatin First-Line Treatment Metastatic Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm locally advanced ( T4b , N ; T , N23 ) , metastatic ( M1 ) urothelial carcinoma bladder , ureter , urethra , renal pelvis enrol institution . Patients mixed histology require predominant urothelial component review pathologist enrol institution . Age ≥18 year Life expectancy ≥ 12 week The patient must least two site measurable disease ( per RECIST v1.1 ; see Appendix 2 ) . Additionally , one sit must amenable biopsy , opinion investigator and/or interventional radiologist , likely yield acceptable tumor sample core biopsy per pathology criterion . Lesions biopsied may consider target lesion per RECIST v1.1 . Subject must agree undergo two researchdirected biopsy treatment . Patients must adequate tumor tissue available PDL1 testing . Adequate tumor tissue define : For coreneedle biopsy specimen , least three core submit evaluation . Acceptable sample include coreneedle biopsy deep tumor tissue ( minimum three core ) excisional , incisional , punch , forceps biopsy cutaneous , subcutaneous , mucosal lesion . Samples collect fineneedle aspiration , brushing , cell pellet pleural effusion , bone metastasis without soft tissue component , lavage acceptable . For pretreatment archival tissue , representative urothelial carcinoma FFPE tumor specimen ( tumor block 30 unstained slide ) must provide . Patients &lt; 30 slide may enrol discussion MSK Principal Investigator . Primary metastatic specimen ( exception bone evaluable PDL1 expression ) may submit . Adequate hematologic end organ function , define follow laboratory result obtain within 14 day prior first study treatment ( Cycle 1 , Day 1 ) : ANC ≥ 1500 cells/uL WBC count &gt; 2500/uL Lymphocyte count ≥ 300/uL Platelet count ≥ 100,000/uL ; Hemoglobin ≥ 9.0 g/dL Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) follow exception : Patients know Gilbert disease total bilirubin level ≤ 3 x ULN may enrol . AST ALT ≤ 3.0 x ULN follow exception : °Patients liver metastasis may enroll AST ALT ≤ 5 x ULN Alkaline phosphatase ≤ 2.5 x ULN follow exception : °Patients document liver bone metastasis may enroll alkaline phosphatase ≤ 5 x ULN Estimated glomerular filtration rate ≥ 60 ml/min/1.73m^2 use CKDEPI equation : eGFR = 141 x min ( Scr/k , 1 ) x max ( Scr/k , 1 ) 1.209 x 0.993Age x 1.018 [ female ] x 1.159 [ black ] Scr serum creatinine , k 0.7 female 0.9 male , 0.329 female 0.411 male , min indicate minimum Scr/k 1 , max indicate maximum Scr/k 1 For female patient childbearing potential male patient partner childbearing potential , agreement ( patient and/or partner ) use highly effective form ( ) contraception ( i.e. , one result low failure rate [ &lt; 1 % per year ] use consistently correctly ) continue use 5 month last dose atezolizumab . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 INR aPTT ≤ 1.5 x ULN This apply patient receive therapeutic anticoagulation ; patient receive therapeutic anticoagulation ( lowmolecularweight heparin warfarin ) stable dose . Ability willingness comply requirement study protocol Prior chemotherapy immunotherapy metastatic urothelial cancer . Prior neoadjuvant adjuvant chemotherapy first progression &gt; 12 month allow . Prior intravesical treatment BCG allow , however BCG allow within 4 week prior initiation study treatment . Any approved anticancer therapy , include chemotherapy , hormonal therapy , radiotherapy , within 3 week prior initiation study treatment ; however , follow allow : Hormonereplacement therapy oral contraceptive Herbal therapy &gt; 1 week prior Cycle 1 , Day 1 . Herbal therapy intend anticancer therapy must also discontinue least 1 week prior Cycle 1 , Day 1 . Palliative radiotherapy bone metastases &gt; 2 week prior Cycle 1 , Day 1 Bisphosphonate therapy symptomatic hypercalcemia °Use bisphosphonate therapy reason ( e.g. , bone metastasis osteoporosis ) allow . Known clinically significant liver disease , include active viral , alcoholic , hepatitis ; cirrhosis ; fatty liver ; inherit liver disease Patients history active bone marrow disorder expect interfere study therapy ( e.g . acute leukemia , accelerated/blastphase chronic myelogenous leukemia , chronic lymphocytic leukemia , Burkitt lymphoma , plasma cell leukemia , nonsecretory myeloma ) Known primary central nervous system ( CNS ) malignancy symptomatic CNS metastasis °Evaluable measurable disease outside CNS No metastases brain stem , midbrain , pons , medulla , cerebellum , within 10 mm optic apparatus ( optic nerve chiasm ) No history intracranial hemorrhage spinal cord hemorrhage No ongoing requirement dexamethasone CNS disease ; patient stable dose anticonvulsant permit . No neurosurgical resection brain biopsy within 28 day prior Cycle 1 , Day 1 Patients asymptomatic treat CNS metastasis may enrol , provide criterion list met well follow : Radiographic demonstration improvement upon completion CNSdirected therapy evidence interim progression completion CNSdirected therapy screen radiographic study No stereotactic radiation wholebrain radiation within 28 day prior Cycle 1 , Day 1 Screening CNS radiographic study ≥ 4 week completion radiotherapy ≥ 2 week discontinuation corticosteroid Pregnancy , lactation , breastfeed . Sensory motor peripheral neuropathy ≥ grade 2 Hearing loss ≥ grade 2 Known hypersensitivity Chinese hamster ovary cell product recombinant human antibody Inability comply study followup procedure History risk autoimmune disease , include limited systemic lupus erythematosus , rheumatoid arthritis , inflammatory bowel disease , vascular thrombosis associate antiphospholipid syndrome , Wegener 's granulomatosis , Sjögren 's syndrome , Bell 's palsy , GuillainBarré syndrome , multiple sclerosis , autoimmune thyroid disease , vasculitis , glomerulonephritis Patients history autoimmune hypothyroidism stable dose thyroid replacement hormone may eligible . Patients control Type 1 diabetes mellitus stable insulin regimen may eligible . Patients eczema , psoriasis , lichen simplex chronicus vitiligo dermatologic manifestation ( e.g. , patient psoriatic arthritis would exclude ) permit provided meet following condition : Patients psoriasis must baseline ophthalmologic exam rule ocular manifestation Rash must cover less 10 % body surface area ( BSA ) Disease well control baseline require low potency topical steroid ( e.g. , hydrocortisone 2.5 % , hydrocortisone butyrate 0.1 % , flucinolone 0.01 % , desonide 0.05 % , aclometasone dipropionate 0.05 % ) No acute exacerbation underlie condition within last 12 month ( i.e . require psoralen plus ultraviolet A radiation [ PUVA ] , methotrexate , retinoids , biologic agent , oral calcineurin inhibitor ; high potency oral steroid ) History idiopathic pulmonary fibrosis , pneumonitis ( include drug induce ) , organize pneumonia ( i.e. , bronchiolitis obliterans , cryptogenic organize pneumonia , etc . ) , evidence active pneumonitis screen chest compute tomography ( CT ) scan °History radiation pneumonitis radiation field ( fibrosis ) permit . Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication History HIV infection active hepatitis B ( chronic acute ) hepatitis C infection Patients past resolve hepatitis B infection ( define negative hepatitis B surface antigen [ HBsAg ] test positive antiHBc [ antibody hepatitis B core antigen ] antibody test ) eligible . Patients positive hepatitis C virus ( HCV ) antibody eligible polymerase chain reaction ( PCR ) negative HCV RNA . Active tuberculosis Severe infection within 4 week prior Cycle 1 , Day 1 , include limited hospitalization complication infection , bacteremia , severe pneumonia Signs symptom infection within 2 week prior Cycle 1 , Day 1 Received oral IV antibiotic within 2 week prior Cycle 1 , Day 1 °Patients receive prophylactic antibiotic ( e.g. , prevention urinary tract infection chronic obstructive pulmonary disease ) eligible . Major surgical procedure within 28 day prior Cycle 1 , Day 1 anticipation need major surgical procedure course study Administration live , attenuated vaccine within 4 week Cycle 1 , Day 1 anticipation live , attenuated vaccine require study °Influenza vaccination give influenza season ( approximately October March ) . Patients must receive live , attenuate influenza vaccine ( e.g. , FluMist® ) within 4 week prior Cycle 1 , Day 1 time study . Malignancies disease study within 5 year prior Cycle 1 , Day 1 , exception negligible risk metastasis death expect curative outcome ( adequately treat carcinoma situ cervix , basal squamous cell skin cancer , localize prostate cancer treat surgically curative intent , ductal carcinoma situ treat surgically curative intent ) undergo active surveillance per standardofcare management ( e.g. , chronic lymphocytic leukemia Rai Stage 0 , prostate cancer Gleason score ≤ 6 , prostatespecific antigen [ PSA ] ≤ 10 mg/mL , etc . ) Prior treatment antiPD1 , antiPDL1 therapeutic antibody pathwaytargeting agent °Patients receive prior treatment antiCTLA4 may enrol , provide follow requirement meet : Minimum 12 week first dose antiCTLA4 &gt; 6 week last dose No history severe immunerelated adverse effect antiCTLA4 ( NCI CTCAE Grade 3 4 ) Treatment systemic immunostimulatory agent ( include limit interferon [ IFN ] interleukin [ IL ] 2 ) within 6 week five halflives drug ( whichever short ) prior Cycle 1 , Day 1 Treatment investigational agent within 4 week prior Cycle 1 , Day 1 ( within five halflives investigational product , whichever long ) Treatment systemic immunosuppressive medication ( include limit prednisone , cyclophosphamide , azathioprine , methotrexate , thalidomide , antitumor necrosis factor [ antiTNF ] agent ) within 2 week prior Cycle 1 , Day 1 Patients receive acute , lowdose , systemic immunosuppressant medication ( e.g. , onetime dose dexamethasone nausea ) may enrol . The use inhale corticosteroid mineralocorticoid ( e.g. , fludrocortisone ) allow . History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion proteins Patients prior allogeneic bone marrow transplantation prior solid organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Gemcitabine</keyword>
	<keyword>Atezolizumab</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>16-1621</keyword>
</DOC>